Synthekine has no published valuation. The company is private, so there is no listed share price.
Synthekine is a biotechnology company that applies protein engineering platforms to develop cytokine therapeutics for cancer and autoimmune disease, aiming to unlock the efficacy of cytokines while avoiding the toxicity that comes from their pleiotropic effects on the immune system.
Synthekine's total funding stands at $289.5M over 3 rounds.
Synthekine's most recent round was Series B, raising $107.5M in June 2021.
Synthekine's lead investors include Deerfield Management and Janus Henderson Investors.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
